Impact of a pharmacist-driven care package on Staphylococcus aureus bacteremia management in a large community healthcare network: A propensity score-matched, quasi-experimental study

Smith, Jordan R.; Frens, Jeremy J; Snider, Cynthia B.; Claeys, Kimberly C

doi:10.1016/j.diagmicrobio.2017.10.001

Cited by 22 publications

(10 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mortality rates for patients with Staphylococcus aureus ( S. aureus ) infections have improved only modestly in recent decades and S. aureus infections remain a major clinical challenge [ 1 ]. Indeed, multi-drug resistant S. aureus has been reported worldwide and its rates are increasing, particularly MRSA, where only last resort antibiotics can be used, such as tigecycline, daptomycin, and linezolid [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Eravacycline activity against clinical S. aureus isolates from China: in vitro activity, MLST profiles and heteroresistance

Zhang

Bai

et al. 2018

BMC Microbiol

View full text Add to dashboard Cite

BackgroundMortality rates for patients with Staphylococcus aureus (S. aureus) infections have improved only modestly in recent decades and S. aureus infections remain a major clinical challenge This study investigated the in vitro antimicrobial activity of erevacycline (erava) against clinical S. aureus isolates from China, as well as the heteroresistance frequency of erava and sequence types (STs) represented in the sample.ResultsA sample of 328 non-duplicate clinical S. aureus isolates, including 138 methecillin-resistant (MRSA) and 190 methecillin-sensitive (MSSA) isolates, were collected retrospectively in China. Erava exhibited excellent in vitro activity (MIC50 ≤ 0.25 mg/L) against MRSA and MSSA, including isolates harboring Tet specific resistance genes. The frequency of erava heteroresistance in MSSA with erava MICs = 0.5 mg/L was 13.79% (4/29); no MRSA with erava MICs ≤0.5 mg/L exhibited heteroresistance. Heteroresistance- derived clones had no 30S ribosome subunit mutations, but their erava MICs (range, 1–4 mg/L) were suppressed dramatically in the presence of efflux protein inhibitors.ConclusionsConclusively, erava exhibited excellent in vitro activity against S. aureus, however hints of erava heteroresistance risk and MIC creep were detected, particularly among MSSA with MICs of 0.5 mg/L.Electronic supplementary materialThe online version of this article (10.1186/s12866-018-1349-7) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

Eravacycline activity against clinical S. aureus isolates from China: in vitro activity, MLST profiles and heteroresistance

Zhang

Bai

et al. 2018

BMC Microbiol

View full text Add to dashboard Cite

show abstract

“…ASP is instituted to promote the appropriate use of antimicrobials, improve patient outcome, reduce microbial resistance, and decrease the spread of infection caused by multidrug-resistant organisms (Charani et al, 2019). Meanwhile, the inclusion of clinical pharmacists in ASP has been shown to result in significant improvement in terms of the quality of antibiotic use from various aspects, such as improving guidelineconcordant antimicrobial prescribing (Smith et al, 2018;Wang et al, 2018;Fay et al, 2019;Bishop et al, 2020), lessening the emergence of multidrug resistance (Li et al, 2017), shortening the days of antibiotic therapy (Wirtz et al, 2020), reducing the hospital stay of patients (Sadyrbaeva-Dolgova et al, 2020), and decreasing patients mortality (Li et al, 2017). ASP in China was initiated in 2011 with the promulgation of the Guideline for Clinical Application of Antimicrobial Agents (GCAAA), which required clinical pharmacists to participate in the management of antimicrobials, particularly in special antibiotics (vancomycin, carbapenem, tigecycline).…”

Section: Introductionmentioning

confidence: 99%

The Effectiveness of Clinical Pharmacist-Led Consultation in the Treatment of Infectious Diseases: A Prospective, Multicenter, Cohort Study

Zhang

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Antimicrobial resistance (AMR) is a serious global health threat and leads to a huge challenge to infectious diseases (ID) treatment. To tackle AMR, regional 'Antimicrobial Stewardship Programs' (ASP) have been implemented in many countries. Due to insufficient clinical pharmacy resources, a major intervention mode of ASP in China is through clinical pharmacist-led consultation (CPC). The current study aims to prospectively evaluate this intervention and compare the effectiveness of CPC served by ID and non-ID clinical pharmacists. Methods: We conducted a prospective and multicenter cohort study based on a regional registry database in 17 hospitals in Western China, including consecutive patients with ID between April 2017 and December 2019. Baseline characteristics including sex, age, liver and kidney function, comorbidity, infection severity were prospectively collected and recorded. The main exposure of interest was whether the attending physician adopted recommendations of the clinical pharmacist in the therapeutic scheme. The outcome was the infection effective response, assessed during day 3-7 after completing CPC. Multivariate analyses were performed by generalized linear mixed models. Results: A total of 2,663 ID patients were included in the final analysis according to the predesigned inclusion and exclusion criteria. The number of patients whose treatment followed

show abstract

“…Pharmacy; predictors; readmission; risk; prediction; model Background Preventable 30-day readmissions put patients at risk of hospital-acquired infections, increase healthcare costs, and put health systems at risk for fiscal penalties by the Centers of Medicare & Medicaid Services (CMS) Hospital Readmissions Reduction Program 1 . Pharmacist-led interventions during transitions of care have shown potential in reducing hospital readmission rates [2][3][4][5][6][7][8] and medication errors 9,10 . These pharmacist-led interventions include medication reconciliation 8,10 , complete medication reviews during admission 7,8 and medication therapy management programs after discharge 11,12 .…”

Section: Introductionmentioning

confidence: 99%

The Impact of Pharmacy-specific Predictors on the Performance of 30-Day Readmission Risk Prediction Models

Kabue¹,

Greene

Kipnis

et al. 2019

Medical Care

View full text Add to dashboard Cite

Research Objective-Pharmacists are an expensive and limited resource in the hospital and outpatient setting. A pharmacist can spend up to 25% of their day planning. Time spent planning is time not spent delivering an intervention. A readmission risk adjustment model has potential to be used as a universal outcome-based prioritization tool to help pharmacists plan their interventions more efficiently. Pharmacy-specific predictors have not been used in the constructs of current readmission risk models. We assessed the impact of adding pharmacy-specific predictors on performance of readmission risk prediction models. Study Design-We used an observational retrospective cohort study design to assess whether pharmacy-specific predictors such as an aggregate pharmacy score and drug classes would

show abstract

Impact of a pharmacist-driven care package on Staphylococcus aureus bacteremia management in a large community healthcare network: A propensity score-matched, quasi-experimental study

Cited by 22 publications

References 26 publications

Eravacycline activity against clinical S. aureus isolates from China: in vitro activity, MLST profiles and heteroresistance

Eravacycline activity against clinical S. aureus isolates from China: in vitro activity, MLST profiles and heteroresistance

The Effectiveness of Clinical Pharmacist-Led Consultation in the Treatment of Infectious Diseases: A Prospective, Multicenter, Cohort Study

The Impact of Pharmacy-specific Predictors on the Performance of 30-Day Readmission Risk Prediction Models

Contact Info

Product

Resources

About